Skip to contentH
HCW Biologics Inc.
H
HCWBHCW Biologics Inc. Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$394.80K$394.80Kderived−70.2% vs Q4 2023 Net Income-$3.37M-$3.37MderivedN/M vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
HCW Biologics Inc. · CIK 1828673 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$78,960−68.7% Operating Incomederived-$3,142,307N/M Operating Cash Flowderived-$2,834,881N/M Free Cash Flowderived-$2,948,293N/M Margins · derivedGross margin20.0%+0.9 pt vs Q4 2023
Operating margin-795.9%+17.4 pt vs Q4 2023
Net margin-854.4%−47.7 pt vs Q4 2023
ended Dec 31, 2024 · filed Mar 28, 2025 · 87 d after period end